| Literature DB >> 26927101 |
Abstract
A search of the current scientific literature yields a limited number of studies that describe the use of Fourier transform infrared (FT-IR) spectroscopic imaging for the analysis of forensic casework, which is likely due to the fact that these instruments are fairly new commodities to the field of analytical chemistry and are therefore not yet commonplace in forensic laboratories. This report describes recent forensic case studies that have used the technique for determining the composition of a wide variety of multi-component sample types, including animal tissue sections for toxic inclusions, drugs/dietary supplements, an antibiotic with an active pharmaceutical ingredient (API) present as several different salt forms, an adulterated bulk API, unknown trace powders for illicit drugs and an ophthalmic solution suspected of being adulterated with bleach.Entities:
Keywords: adulteration; dietary supplement; forensic science; infrared spectroscopic imaging; melamine cyanurate
Mesh:
Substances:
Year: 2016 PMID: 26927101 PMCID: PMC4813853 DOI: 10.3390/s16030278
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1Visible image (a); R/A correlation image for melamine cyanurate (b); overlay image of (a) and (b), (c); representative R/A spectrum from a low correlation region (d); representative R/A spectrum from a high correlation region (e); ATR spectrum from a high correlation region (f); and ATR spectrum of a melamine cyanurate pure compound reference standard (g).
Combination drugs and multi- active pharmaceutical ingredient (API) dietary supplements examined by the Forensic Chemistry Center (FCC) using FT-IR spectroscopic imaging.
| Combination Drugs | Dosage (s) | Active Ingredient (s) |
|---|---|---|
| Anti-malarial | 250/100 mg | atovaquone, praguanil HCl |
| Cholesterol | 80/10 mg, 40/10 mg | ezetimbe, simvastatin |
| HIV | 300/150 mg | lamivudine, zidovudine |
| HIV | 300/200 mg | tenofovir disoproxil fumarate, emtricitibine |
| Hypertension | 320/25, 320/12.5 mg | valsartan, hydrochlorothiazide |
| Hypertension | 320/10, 160/10 mg, 160/5 mg | valsartan, amlodipine besylate |
| Hypertension | 100/12.5 mg, 50/12.5 mg | losartan potassium, hydrochlorothiazide |
| Hypertension | 160/150 mg | valsartan, aliskiren |
| Hypertension | 40/12.5 mg | olmesartan medoxomil, hydrochlorothiazide |
| Hypertension | 300/12.5 mg, 150/25 mg, 150/12.5 mg | aliskiren hemifumarate, hydrochlorothiazide |
| Hypertension/Angina | 40/5 mg | atorvastatin, amlodipine besylate |
| Pain Reliever | 300/50/40 mg | acetaminophen, butalbital, caffeine |
| Pain Reliever | 325/10 mg, 325/5 mg | acetaminophen, oxycodone HCl |
| Pain Reliever | 325/10 mg | acetaminophen, hydrocodone bitartrate |
| Parkinson’s | 100/100/200 mg | carbidopa, levodopa, entacapone |
| Type 2 Diabetes | 1000/50 mg, 500/50 mg | metformin HCl, sitagliptin |
| 1 | aegeline, higenamine HCl, caffeine | |
| 2 | aegeline, caffeine | |
| 3 | ascorbic acid, n-acetyl-l-cysteine, p-aminobenzoic acid | |
| 4 | ubiquinone, starch, inorganic stearate, microcrystalline | |
| 5 | creatine, starch, inorganic stearate | |
| 6 | 1,3 dimethylpentylamine, glaucine, cellulose, talc | |
| 7 | caffeine, cellulose, inorganic carbonate, | |
| 8 | phenolphthalein, tetracaine HCl, fenfluramine, | |
| 9 | phenolphthalein, acetaminophen, propanolol HCl | |
| 10 | tadalafil, gelatin | |
Figure 2ATR-FT-IR image of the suspect product (a); and representative spectra from the blue (b); green (d) and red (f) regions compared to pure compound reference spectra of penicillin G sodium salt (c); penicillin G procaine salt hydrate (e) and penicillin G benzathine salt (g).
Figure 3ATR-FT-IR image of the bulk API (a); representative spectrum from the gray region (b); pure compound reference spectrum of the API (c); representative spectrum from the green region (d); pure compound reference spectrum of sodium sulfate (e).
Figure 4ATR-FT-IR image of Powder 1 (a); and representative spectra from the cyan (b); purple (c) and gray (d) regions compared to a pure compound reference spectrum of cocaine HCl (e); IR image of Powder 2 (f); and representative spectra from the cyan (g); red (h); blue (i) and yellow (j) regions compared to a pure compound reference spectrum of methandrostenolone (k).
Figure 5Reflection/absorption-IR images of the suspect dried residue (a); control dried residue (b) and control spiked with bleach dried residue (c); representative spectra from the blue region in the suspect image (d); control image (e) and control spiked with bleach image (f); representative spectra from the red region in the suspect image (g); green region in the control image (h) and red region in the control spiked with bleach image (i).